Format

Send to

Choose Destination
Oncotarget. 2015 Aug 21;6(24):19976-89.

Going viral: a review of replication-selective oncolytic adenoviruses.

Author information

1
University of California at San Diego (UCSD), Moores Cancer Center, La Jolla, CA, USA.
2
EpicentRx, Inc., Mountain View, CA, USA.
3
InterWest Partners, Menlo Park, CA, USA.

Abstract

Oncolytic viruses have had a tumultuous course, from the initial anecdotal reports of patients having antineoplastic effects after natural viral infections a century ago to the development of current cutting-edge therapies in clinical trials. Adenoviruses have long been the workhorse of virotherapy, and we review both the scientific and the not-so-scientific forces that have shaped the development of these therapeutics from wild-type viral pathogens, turning an old foe into a new friend. After a brief review of the mechanics of viral replication and how it has been modified to engineer tumor selectivity, we give particular attention to ONYX-015, the forerunner of virotherapy with extensive clinical testing that pioneered the field. The findings from those as well as other oncolytic trials have shaped how we now view these viruses, which our immune system has evolved to vigorously attack, as promising immunotherapy agents.

KEYWORDS:

adenovirus; immunotherapy; oncology; oncolytic virus

PMID:
26280277
PMCID:
PMC4652981
DOI:
10.18632/oncotarget.5116
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center